Clin2
NCT06969170Possibly a fitRecruiting

Psilocybin oral solution for generalized anxiety disorder trial

Generalized Anxiety Disorder (GAD)

Treatments studied

Part of Mental health clinical trials.

This study tests a psilocybin oral solution in adults with generalized anxiety disorder (GAD). It aims to see if the drug is safe, tolerable, and helpful for reducing anxiety symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
50 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • You are between 18 and 60 years old.
  • You have been diagnosed with generalized anxiety disorder (GAD) for at least 1 year.
  • Your anxiety symptoms are moderate to severe (score of 14 or higher on a standard anxiety scale).
  • You are not currently taking daily medications for anxiety or depression, or you are willing to stop them 4 weeks before the study starts.
  • You have no history of bipolar disorder, psychosis, severe depression, panic disorder, or other serious mental health conditions.
  • You have not had suicidal thoughts in the past year.
  • You are willing to avoid pregnancy or fathering a child during the study and for 30 days after.
  • You have not used psychedelic drugs more than once in the past 6 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07123467Recruiting· Phase 3
Study on CBD and learning for generalized anxiety

This trial tests if adding cannabidiol (CBD) to a learning-based approach helps manage generalized anxiety disorder (GAD). It involves brain scans and taking CBD daily.

Detroit, Michigan
NCT06512220Recruiting· Phase 2
Psilocybin for treatment-resistant depression brain imaging study

This study tests whether a psilocybin-based treatment can help people with depression that has not improved after trying several antidepressants. You will receive the study treatment and have brain scans to see how it affects brain connections.

Toronto, Ontario
NCT07767903Recruiting· Phase 3
Study of a new medicine for generalized anxiety disorder

This trial tests an investigational medication to see if it can reduce anxiety symptoms in adults with generalized anxiety disorder. Participants will receive the study drug and be monitored for safety and effectiveness.

Cherry Hill, New Jersey
NCT07759128Recruiting· Phase 3
Test of a new anxiety medication for adults with generalized anxiety disorder

This study tests a new medicine (SEP-363856) for adults with generalized anxiety disorder to see if it reduces anxiety symptoms and is safe. It may help if other treatments haven't worked well.

Jacksonville, Florida
NCT07786454Not yet recruiting· Phase 3
Extended treatment for generalized anxiety disorder

This trial tests whether an already-studied medication, SEP-363856, can continue to safely help adults with generalized anxiety disorder over a longer period. It may offer ongoing symptom relief for people who completed a previous study of this drug.

NCT07478744Recruiting· Phase 2
Study for generalized anxiety disorder with SYT-510

This trial tests a new medicine called SYT-510 for adults with generalized anxiety disorder who are not currently taking medication. It aims to see if the drug reduces anxiety and is safe.

London

Hear when a new Generalized Anxiety Disorder (GAD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.